BioCentury | Oct 13, 2017
Clinical News

Medix Products begins Phase III of obesity candidate

...>5% and >10%, metabolic and glycemic endpoints, quality of life (QOL) and safety. In 2014, NeuroSearch A/S...
...to tesofensine in Mexico and Argentina. Medix Products S.A. de C.V. , Mexico City, Mexico NeuroSearch A/S...
...and safety Status: Phase III start Milestone: Complete Phase III (2019) Chris Lieu NS2330 tesofensine Medix Products S.A. de C.V. NeuroSearch A/S Saniona...
BioCentury | Sep 19, 2016
Clinical News

Teva HD candidate pridopidine heading for Phase III

...plans to request an end-of-Phase II meeting with FDA. Teva obtained rights to pridopidine from NeuroSearch A/S...
BioCentury | Sep 28, 2015
Regulation

Serving nerves

...May by acquiring Auspex Pharmaceuticals Inc. , and Huntexil pridopidine, a dopamine stabilizer in-licensed from NeuroSearch A/S...
...Massachusetts General Hospital, Boston, Mass. National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Md. NeuroSearch A/S...
BioCentury | Apr 6, 2015
Strategy

Teva says I deu

...and other movement disorder aspects, but not chorea. The company in-licensed the dopamine stabilizer from NeuroSearch A/S...
...Minneapolis, Minn. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Genentech Inc., South San Francisco, Calif. NeuroSearch A/S...
BioCentury | Nov 24, 2014
Company News

NeuroSearch, Saniona deal

...and tesofensine (NS2330). Saniona will assume the cost of maintaining patent rights to the compounds. NeuroSearch...
...inhibitor, has completed Phase II testing to treat obesity, Alzheimer’s disease (AD) and Parkinson’s disease. NeuroSearch A/S...
BioCentury | Oct 20, 2014
Company News

NeuroSearch neurology news

...of improving voluntary motor function. The data were subsequently reassessed and on April 28, 2010, NeuroSearch...
...Huntexil did not meet the primary endpoint in the trial (see BioCentury, July 29, 2013). NeuroSearch...
...Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) acquired NeuroSearch's Huntexil, a dopamine stabilizer. At June 30, NeuroSearch...
BioCentury | Sep 29, 2014
Company News

Saniona, NeuroSearch, J&J deal

...2009 deal to discover and develop therapeutics for CNS diseases. The deal was originally between NeuroSearch...
...and Janssen, but was transferred to Saniona in 2012 when the company bought parts of NeuroSearch's...
...royalties (see BioCentury, Aug. 24, 2009 & May 23, 2011). Saniona AB (AktieTorget:SANION), Ballerup, Denmark NeuroSearch A/S...
BioCentury | May 5, 2014
Clinical News

Pridopidine: Phase II started

...years with an onset of HD after 18 years of age. Teva gained pridopidine from NeuroSearch A/S...
BioCentury | Mar 20, 2014
Financial News

Saniona raises $2.7 million in Swedish IPO

...a monoamine reuptake inhibitor. Saniona became operational in 2012 when NeuroSearch A/S (CSE:NEUR) transferred to Saniona NeuroSearch's...
BioCentury | Nov 25, 2013
Company News

NeuroSearch board of directors update

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Business: Neurology Appointed: Christian Lundgren, a director, as provisional chairman, effective Dec. 1; he succeeds Allan Andersen, who will transition to CEO; Andersen, succeeds Rene Schneider, who is resigning WIR...
Items per page:
1 - 10 of 388
BioCentury | Oct 13, 2017
Clinical News

Medix Products begins Phase III of obesity candidate

...>5% and >10%, metabolic and glycemic endpoints, quality of life (QOL) and safety. In 2014, NeuroSearch A/S...
...to tesofensine in Mexico and Argentina. Medix Products S.A. de C.V. , Mexico City, Mexico NeuroSearch A/S...
...and safety Status: Phase III start Milestone: Complete Phase III (2019) Chris Lieu NS2330 tesofensine Medix Products S.A. de C.V. NeuroSearch A/S Saniona...
BioCentury | Sep 19, 2016
Clinical News

Teva HD candidate pridopidine heading for Phase III

...plans to request an end-of-Phase II meeting with FDA. Teva obtained rights to pridopidine from NeuroSearch A/S...
BioCentury | Sep 28, 2015
Regulation

Serving nerves

...May by acquiring Auspex Pharmaceuticals Inc. , and Huntexil pridopidine, a dopamine stabilizer in-licensed from NeuroSearch A/S...
...Massachusetts General Hospital, Boston, Mass. National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Md. NeuroSearch A/S...
BioCentury | Apr 6, 2015
Strategy

Teva says I deu

...and other movement disorder aspects, but not chorea. The company in-licensed the dopamine stabilizer from NeuroSearch A/S...
...Minneapolis, Minn. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Genentech Inc., South San Francisco, Calif. NeuroSearch A/S...
BioCentury | Nov 24, 2014
Company News

NeuroSearch, Saniona deal

...and tesofensine (NS2330). Saniona will assume the cost of maintaining patent rights to the compounds. NeuroSearch...
...inhibitor, has completed Phase II testing to treat obesity, Alzheimer’s disease (AD) and Parkinson’s disease. NeuroSearch A/S...
BioCentury | Oct 20, 2014
Company News

NeuroSearch neurology news

...of improving voluntary motor function. The data were subsequently reassessed and on April 28, 2010, NeuroSearch...
...Huntexil did not meet the primary endpoint in the trial (see BioCentury, July 29, 2013). NeuroSearch...
...Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) acquired NeuroSearch's Huntexil, a dopamine stabilizer. At June 30, NeuroSearch...
BioCentury | Sep 29, 2014
Company News

Saniona, NeuroSearch, J&J deal

...2009 deal to discover and develop therapeutics for CNS diseases. The deal was originally between NeuroSearch...
...and Janssen, but was transferred to Saniona in 2012 when the company bought parts of NeuroSearch's...
...royalties (see BioCentury, Aug. 24, 2009 & May 23, 2011). Saniona AB (AktieTorget:SANION), Ballerup, Denmark NeuroSearch A/S...
BioCentury | May 5, 2014
Clinical News

Pridopidine: Phase II started

...years with an onset of HD after 18 years of age. Teva gained pridopidine from NeuroSearch A/S...
BioCentury | Mar 20, 2014
Financial News

Saniona raises $2.7 million in Swedish IPO

...a monoamine reuptake inhibitor. Saniona became operational in 2012 when NeuroSearch A/S (CSE:NEUR) transferred to Saniona NeuroSearch's...
BioCentury | Nov 25, 2013
Company News

NeuroSearch board of directors update

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Business: Neurology Appointed: Christian Lundgren, a director, as provisional chairman, effective Dec. 1; he succeeds Allan Andersen, who will transition to CEO; Andersen, succeeds Rene Schneider, who is resigning WIR...
Items per page:
1 - 10 of 388